Plasma Fractionation Market to Grow at a CAGR of 7.1% During 2022-2029; Acquisition of Plasma Donation Centre Allows Grifols S.A. to Enhance Medicine Availability

The global plasma fractionation market size was USD 28.69 billion in 2021. The market is projected to grow from USD 30.64 billion in 2022 to USD 49.61 billion by 2029 at a CAGR of 7.1% during the 2022-2029 period.

Fortune Business Insights™ publishes this information in its report titled, "Plasma Fractionation Market Size, Share & COVID-19 Impact Analysis, By Product (Albumin, Immunoglobulin (Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)), Coagulation Factors (Factor IX, Factor VIII, Prothrombin Complex Concentrates, Fibrinogen Concentrates, Others), Protease Inhibitors, Others), By Application (Immunology & Neurology, Hematology, Critical Care, Pulmonology, Others), By End-user (Hospitals & Clinics, Clinical Research Laboratories, Others), and Regional Forecast, 2022-2029."

Restrictions on Plasma Collection Operations Amid Pandemic Hampered Market Growth

The outbreak of COVID-19 pandemic created a huge impact on several businesses owing to stringent restrictions and limitations on operations imposed by governments. Also, due to the rising number of COVID-19 cases, hospitals were entirely occupied by emergency cases, and plasma therapies for non-critical cases were not prioritized during the initial lockdown phase. Plasma collection operations were halted, which impacted the plasma fractionation market growth during the pandemic period.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614

Grifols S.A. Acquired its First Plasma Donation Centre

Grifols S.A. acquired Prometic Plasma Resources Inc’s (PPR), its first donation center. This strategic acquisition will allow the company to ensure the availability of plasma medicines in the Canada. Also, the company can gain easy access to plasma which helps the organization's profitability and enhance its organizational productivity.

Rising Technological Advancements in Healthcare Sector to Propel Growth  

The market of plasma fractionation is projected to grow prominently in the coming years owing to the launch of new technologies by leading market players, which is expected to bolster the market growth. Also, increasing demand for plasma-derived medicinal products supported the market reach in developed and developing countries. Furthermore, the surging incidences of immunodeficiency disorders are anticipated to drive the market development and expansion during the forecast period.

Strategic Acquisitions Allow Companies to Expand Medicinal Availability

The key players of plasma fractionation implement various strategies to enhance their business performance. The leading companies form strategic alliances, partnerships, mergers, and acquisitions to expand their business reach and strengthen their market position. Strategic acquisitions allow companies to expand their business reach and enhance the availability of medicines.  

Notable Industry Development:

• January 2022: Grifols, S.A. announced the acquisition of its first donation center, Prometic Plasma Resources Inc’s (PPR), from Kedrion in Canada, as a part of the company’s commitment to expanding the availability of lifesaving plasma medicines in the country.

List of Key Players Covered in the Report:

• CSL (U.S.)


• Grifols, S.A (Spain)


• Takeda Pharmaceutical Company Limited (Japan)


• Kedrion S.p.A (Italy)


• Octapharma (Switzerland)


• Bio Products Laboratory Ltd. (U.K.)


• Biotest AG (Germany)


• LFB (France)

Further Report Findings:

North America dominates the global plasma fractionation market share due to the emerging technological advancements globally. Furthermore, the presence of leading companies in the region is projected to bolster regional market growth. The regional market registered USD 16.10 billion in 2021.

Based on product, the market is categorized into immunoglobulin, albumin, coagulation factors, protease inhibitors, and others. Also, the immunoglobulin segment is further sub-segmented into intravenous immunoglobulin and subcutaneous immunoglobulin. The coagulation factors segment is sub-segmented into factor IX, factor VIII, prothrombin complex concentrates, fibrinogen concentrates, and others. The protease inhibitors segment is anticipated to dominate the global market due to rising product demand.

Table of Segmentation: